Literature DB >> 21403115

Primary varicella zoster infection associated with fingolimod treatment.

Antonio Uccelli1, Francesca Ginocchio, Giovanni Luigi Mancardi, Matteo Bassetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21403115     DOI： 10.1212/WNL.0b013e31821043b5

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  12 in total

Review 1.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

2.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 3.  Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

4.  [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

5.  New disease-modifying therapies and new challenges for MS.

Authors:  Vijayshree Yadav; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 6.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 7.  Multiple sclerosis treatment and infectious issues: update 2013.

Authors:  A Winkelmann; M Loebermann; E C Reisinger; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 8.  Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.

Authors:  Jacqueline Ann Nicholas; Aaron Lee Boster; Jaime Imitola; Colleen O'Connell; Michael Karl Racke
Journal:  Drug Des Devel Ther       Date:  2014-07-07       Impact factor: 4.162

9.  A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.

Authors:  Anoop K Enjeti; Angel D'Crus; Kathleen Melville; Nicole M Verrills; Philip Rowlings
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

10.  Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study.

Authors:  Julia Rudnicka; Michał Czerwiec; Ewelina Grywalska; Dorota Siwicka-Gieroba; Monika Walankiewicz; Agnieszka Grafka; Michał Zgurski; Agata Surdacka; Halina Bartosik-Psujek; Jacek Roliński
Journal:  Cent Eur J Immunol       Date:  2015-10-15       Impact factor: 2.085
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.